Registry following people newly evaluated for light chain amyloidosis across Europe
Collects information and samples from adults with AL amyloidosis to study the disease.
Key facts
- Who runs it
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Where
- Heidelberg, GermanySee the siteAlso in 5 other countries, 5 sites
- Trial code
- Registry title
- A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 1 Jan 2024
- Planned end
- 1 Jun 2026
- Type of study
- Observational
- Record updated
- 16 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults newly diagnosed with systemic AL amyloidosis who have not yet been treated and will be followed at a participating center.
- Age
- 18 Years to 99 Years
- Sex
- All sexes can join.
- Disease stage
- Diagnosis of systemic AL amyloidosis.
- Earlier treatment
- Must not have had any treatment for AL amyloidosis before (treatment-naïve).
Main reasons for not taking part
- Amyloidosis that is not AL amyloidosis
- Previous treatment for AL amyloidosis
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- diagnosis of systemic AL amyloidosis
- treatment-naïve
- age ≥18 years
- ability to understand and willingness to sign an informed consent
- planned follow-up at participating center
Who cannot take part
- previous treatment for AL amyloidosis
- non-AL amyloidosis
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in Germany
Also in 5 other countries, 5 sites
- Medical Department, Amyloidosis Center, University Hospital, Im Neuenheimer Feld 672Heidelberg, GermanyContact: Stefan Schönland, MDTaking people
About the trial
What the trial wants to find out
A prospective patients' registry collecting all new cases of AL amyloidosis evaluated at referral Centers from across Europe and a sample sharing network will be created to study mechanisms of the disease through the use of advanced molecular technologies and big data analysis tools.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Bonding Molecular Genotyping and Phenotyping to Outcome Measures in AL Amyloidosis: A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
- Plain-language title
- Registry following people newly evaluated for light chain amyloidosis across EuropeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06205953, who can take part
- Record updated
- 16 April 2026